



August 31, 2016

Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- **Galectin Therapeutics Inc.** (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief medical officer, will present at Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 3:50 p.m. Eastern time. The conference is being held at the New York Palace Hotel in New York City on September 11-13, 2016.

A live webcast of the presentation may be accessed on the conference's website at <http://wsw.com/webcast/rshq26/galt>. The webcast and presentation will be archived for 90 days following the event on the company's website at www.galectintherapeutics.com.

About Galectin Therapeutics

Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Contacts:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com